Tatalaksana terkini pada miastenia gravis
Myasthenia gravis (MG) is a disorder of the neuromuscular junction that causes fluctuating muscle weakness. The etiology of this disease is due to the presence of antibodies that attack acetylcholine receptors on the postsynaptic membrane (autoimmune). Myasthenia gravis is a chronic disease and most...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Andalas
2022-10-01
|
| Series: | Majalah Kedokteran Andalas |
| Subjects: | |
| Online Access: | https://jurnalmka.fk.unand.ac.id/index.php/art/article/view/1076 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Myasthenia gravis (MG) is a disorder of the neuromuscular junction that causes fluctuating muscle weakness. The etiology of this disease is due to the presence of antibodies that attack acetylcholine receptors on the postsynaptic membrane (autoimmune). Myasthenia gravis is a chronic disease and most MG patients fall into Generalized Myasthenia Gravis (gMG) within 2 years of onset. Myasthenic crisis is a serious condition and requires high-cost management. Therefore, disease management continues to be updated to reduce mortality and mortality, as well as improve quality of life. This article discusses the latest
myasthenia gravis; guidelines 2020 ; immunosuppressants; plasmaparesis; ivig |
|---|---|
| ISSN: | 0126-2092 2442-5230 |